Vor Biopharma shareholders OK share increase to 800M, re-elect directors

Vor Biopharma Inc.

Authorized common shares increased from 400M to 800M; approved by 65.5M votes for vs 7.7M against.
Class I directors Matthew Patterson and Daniella Beckman re-elected with ~53.4M and ~52.7M votes for.
Ernst & Young LLP ratified as independent auditor for FY2025 with 73.1M votes for.
Annual meeting had 73.2M shares represented, ~58.7% of outstanding.

item 5.03item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.